Akebia Therapeutics (AKBA) vs Keros Therapeutics (KROS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Keros Therapeutics (KROS) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 27.1% versus a loss of 71.4%. Over five years, KROS leads with a -70.1% price change compared with -71.4% for AKBA. Keros Therapeutics is the larger company by market cap ($231.6 million vs $226.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | KROS |
|---|---|---|
| Share price | $0.8154 | $11.68 |
| Market cap | $225.95M | $231.58M |
| 1-day change | +0.07% | +0.34% |
| YTD return | -49.39% | -42.83% |
| 1-year return | -71.41% | -27.07% |
| 5-year return | -71.41% | -70.15% |
| EPS (TTM) | $-0.12 | $-3.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $22.55 |
| 52-week low | $0.805 | $9.69 |
| Distance from 52-week high | -74.52% | -48.20% |
| Analyst consensus | none | buy |
| Avg. price target upside | +380.75% | +69.78% |
| Average volume | 6.18M | 194.05K |
| Shares outstanding | 277.11M | 19.83M |
| Employees | 194 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KROS has outperformed AKBA by 44.3 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
AKBA vs KROS FAQ
Which is bigger, Akebia Therapeutics or Keros Therapeutics?
Keros Therapeutics (KROS) is larger, with a market capitalization of $231.58M compared with $225.95M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or KROS?
KROS returned -27.07% over the past 12 months, compared with -71.41% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Keros Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.